Literature DB >> 2422457

Stereoselectivity at the calcium channel: different profiles of hemodynamic activity of the enantiomers of the dihydropyridine derivative PN 200-110.

R P Hof, A Hof, U T Ruegg, N S Cook, A Vogel.   

Abstract

The enantiomers of PN 200-110 (PN), a highly potent calcium antagonist, were synthesized by a stereoselective synthesis. Cross-contamination was less than 0.2% for the (S)-enantiomer and 0.5% for the (R)-enantiomer. Both isomers inhibited depolarization-induced contraction of rabbit aorta, the (S)-enantiomer being much more active: The pD'2 values were 9.1 and 6.9 for the (S)- and the (R)-enantiomer, respectively. This activity of (R)-PN on potential-operated channels can be attributed to the contamination with 0.5% of (S)-PN. In anesthetized cats, the (S)-enantiomer lowered blood pressure and heart rate dose-dependently (0.3-10 micrograms/kg i.v.). The (R)-enantiomer had almost no effect on heart rate (HR) and blood pressure (BP) at doses up to 300 micrograms/kg. However, both enantiomers increased cardiac output and blood flow to the heart and the brain. The effects on regional blood flow were tissue-dependent, the (R)-enantiomer being surprisingly potent in the subendocardium of the left ventricle. The qualitative and quantitative differences between the activities of the two enantiomers suggest that the results obtained cannot merely be explained by traces of the more active enantiomer contaminating the less active enantiomer. These results, together with those found with the enantiomers of a nitro-substituted dihydropyridine, suggest that calcium channels appear to be able not only to discriminate between enantiomers but also to respond differently to them.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2422457     DOI: 10.1097/00005344-198603000-00001

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

Review 1.  Pharmacology of the calcium antagonist isradipine.

Authors:  U T Rüegg; R P Hof
Journal:  Drugs       Date:  1990       Impact factor: 9.546

2.  Effects of dihydropyridine calcium channel antagonists in ethanol withdrawal; doses required, stereospecificity and actions of Bay K 8644.

Authors:  J M Littleton; H J Little; M A Whittington
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  A Fitton; P Benfield
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

4.  Voltage-gated sodium and calcium currents in rat osteoblasts.

Authors:  D Chesnoy-Marchais; J Fritsch
Journal:  J Physiol       Date:  1988-04       Impact factor: 5.182

5.  Sodium-dependent inhibition by PN200-110 enantiomers of nicotinic adrenal catecholamine release.

Authors:  A M Cárdenas; C Montiel; A R Artalejo; P Sánchez-García; A G García
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

6.  Chronic dihydropyridine treatment can reverse the behavioural consequences of and prevent adaptations to, chronic ethanol treatment.

Authors:  M A Whittington; S J Dolin; T L Patch; R J Siarey; A R Butterworth; H J Little
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

7.  A calcium channel antagonist stereoselectively decreases ethanol withdrawal hyperexcitability but not that due to bicuculline, in hippocampal slices.

Authors:  M A Whittington; H J Little
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

8.  1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.

Authors:  Mauro Cataldi; Fiorentina Bruno
Journal:  Transl Med UniSa       Date:  2012-10-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.